Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.34
-0.4%
$0.39
$0.30
$10.62
$45.30M1.823.44 million shs1.86 million shs
Atreca, Inc. stock logo
BCEL
Atreca
$0.09
$0.09
$0.05
$1.20
$3.57M1.034.61 million shsN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$5.16
+4.2%
$4.43
$2.94
$10.25
$285.95M3.05143,021 shs80,445 shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.21
$0.72
$6.24
$258.25M2.27927,189 shsN/A
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
$1.06
$0.81
$1.99
$136.76M0.84979,585 shs2.77 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
0.00%+4.08%-7.37%-22.51%-92.31%
Atreca, Inc. stock logo
BCEL
Atreca
0.00%0.00%0.00%0.00%0.00%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
0.00%+6.61%+25.24%+50.00%-8.19%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%+0.25%+0.25%+387.09%-10.91%
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
3.8028 of 5 stars
3.31.00.04.70.61.71.3
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
1.8213 of 5 stars
3.60.00.00.02.01.70.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
3.42 of 5 stars
4.24.00.00.01.92.50.0
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
2.50
Moderate Buy$6.101,710.09% Upside
Atreca, Inc. stock logo
BCEL
Atreca
0.00
N/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3.13
Buy$12.13134.98% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BCEL, INZY, APLT, SELB, and FHTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/15/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.00
5/14/2025
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50
5/14/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/30/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.00
4/30/2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$265K180.04N/AN/A$0.49 per share0.69
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/A$2.01 per shareN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$22.60M12.73N/AN/A($0.82) per share-6.29
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
$110.78M0.00N/A9.91$0.61 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)
Atreca, Inc. stock logo
BCEL
Atreca
-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$86.62M-$1.36N/AN/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
$35.38M-$0.22N/AN/AN/A-72.04%-44.13%-22.00%N/A

Latest BCEL, INZY, APLT, SELB, and FHTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
4/14/2025Q4 2024
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/A
3.00
3.00
Atreca, Inc. stock logo
BCEL
Atreca
N/A
1.58
1.58
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/A
3.16
3.16
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
0.21
4.18
4.18

Institutional Ownership

CompanyInstitutional Ownership
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
98.31%
Atreca, Inc. stock logo
BCEL
Atreca
37.47%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
61.55%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
41.95%

Insider Ownership

CompanyInsider Ownership
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
1.60%
Atreca, Inc. stock logo
BCEL
Atreca
11.30%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
7.58%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
31.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
30141.58 million139.31 millionOptionable
Atreca, Inc. stock logo
BCEL
Atreca
13039.62 million35.15 millionOptionable
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
12055.74 million51.52 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
64155.20 million106.78 millionOptionable

Recent News About These Companies

2025 Poinsettias catalog available from Selecta One
2025 Poinsettias catalog available now from Selecta One
Astellas licenses companion drug for Pompe gene therapy
Cartesian Therapeutics Inc (RNAC)
Pared-down Selecta merges with Maryland biotech
Selecta Biosciences Merges With Cartesian Therapeutics In All-stock Deal

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.34 0.00 (-0.38%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$0.34 0.00 (-0.30%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Atreca stock logo

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Foghorn Therapeutics stock logo

Foghorn Therapeutics NASDAQ:FHTX

$5.16 +0.21 (+4.24%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Selecta Biosciences stock logo

Selecta Biosciences NASDAQ:SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.